Choroid Plexus Carcinoma

EVANS, Ga. & AUSTIN, Texas--( BUSINESS WIRE )--The Center for Primary Care (CPC), an independent practice dedicated to providing comprehensive preventative and specialized care, announced today it has formed a new partnership with agilon health inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, accelerating access to value-based primary care in the area. Starting in 2024 through the partnership, CPC will deliver this new model of primary care to further enhance preventative and chronic care for their senior patients. “A value-based approach is the future of health care and agilon understands the importance of exceptional, comprehensive, and affordable value-based primary care,” said Robert M. Clark, D.O., Center for Primary Care. “This partnership will empower our primary care physicians, through a proven model of care, to remain independent and better serve our senior patients while supporting CPC’s mission to provide patients with high-quality care across communities we serve.” CPC, an independent primary care practice, operates across 8 locations in the Central Savannah River Area, which includes communities in Eastern Georgia and Western South Carolina. With 37 primary care physicians (PCPs), CPC is committed to preventative health care as well as the diagnosis and treatment of acute illnesses and chronic conditions. Serving over 76,000 patients of all ages, CPC also offers in-house laboratories and diagnostic imaging services which are exclusively available to their patients. “The newly formed partnership with the Center for Primary Care brings agilon’s Total Care Model to even more communities including senior patients in Eastern Georgia for the first time,” said Steve Sell, chief executive officer, agilon health. “Our team is excited to partner with the Center for Primary Care as they make the move to a full-risk value-based model for their Medicare Advantage patients and primary care physicians.” agilon is accelerating at scale the transition to a value-based, Total Care Model for senior patients that improves outcomes and lowers costs. CPC will join agilon’s 2024 class of new partner organizations, which includes five other physician practices and health systems across the U.S. As of 2024, agilon will be in long-term partnerships with 31 physician groups and health systems across 14 states. About Center for Primary Care (CPC) Center For Primary Care (CPC) is a family and internal medicine practice with 37 primary care physicians and 8 offices in the Central Savannah River Area. CPC's physicians provide comprehensive care for patients of all ages, and diagnostic imaging services. CPC provides weekday evening hours and weekend hours in select locations for established CPC patients with urgent healthcare needs. For more information, visit centerforprimarycare.com . About agilon health agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups transition to a value-based Total Care Model for senior patients. agilon provides the technology, people, capital, process, and access to a peer network of 2,700+ PCPs that allow physician groups to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in 30+ diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information about agilon health, visit www.agilonhealth.com and connect with us on Twitter , Instagram , LinkedIn and YouTube .

ROCKVILLE, Md., Feb. 22, 2023 /PRNewswire/ -- An expert consensus statement published today by the Heart Failure Society of America (HFSA) offers best practices in the management of patients on durable Mechanical Circulatory Support (MCS), focusing on pharmacological therapies administered to patients on continuous flow Left Ventricular Assist Devices (LVADs). "Over the last two decades, durable MCS for the management of advanced heart failure has enjoyed a remarkable evolution, generating smaller and more hemocompatible devices with more favorable side-effect profiles, yielding progressive gains in short- and long-term survival. However, proficient medical management of patients on durable LVAD support is necessary to increase their quantity and quality of life," said Barry Trachtenberg, MD lead author and Cardiologist at Houston Methodist Heart and Vascular Center. "This consensus statement will provide clinicians with practical information they need to make decisions and support optimal patient care for the management of this unique population." As patients live longer on LVAD support, attention to the medical management of patients on durable LVAD support is paramount for advancing long-term outcomes. The consensus statement was created to provide a guide in the following areas: Guideline Directed Medical Therapies in Patients on Durable MCS Medical Therapy Directed at Complications Encountered in Patients on Durable MCS Management of Right Ventricular Failure and Pulmonary Hypertension Identifying and Managing Vasoplegia Perioperatively Management of Strokes Management of Arrhythmias Prevention and Treatment of Mucocutaneous Bleeding Management of Infectious Complications Anticoagulation and Antiplatelet Therapy Management Addressing Depression, Anxiety, and Compliance Consideration of Herbal and Nutritional Therapies The authors highlight the following key points: Postoperative long-term GDMT is recommended for ongoing neurohormonal blockade, prevention of heart failure decompensation, arrhythmia suppression, hypertension control and mitigation of renal vascular disease. Most patients with preoperative pulmonary hypertension will experience improvements in pulmonary pressures following LVAD implant, but a minority will experience cPC-PH that can lead to RV dysfunction. Aggressive preoperative optimization to reduce RV wall stress through decongestion and pulmonary vasodilator therapy, followed by careful postoperative monitoring of RV function and afterload, are critical to reduce the risk of early severe RVF. Ongoing close surveillance of LVAD outpatients, monitoring for congestion or complications that can trigger RV dysfunction (excessive LVAD speeds with septal shift, arrhythmias) are crucial for preventing heart failure exacerbation during long term LVAD therapy. Meticulous driveline care for prevention of driveline and LVAD-associated infections is crucial and prompt use of appropriate antibiotics is crucial in patients with infections Current evidence is reviewed for mitigation and treatment of GIB through pharmacologic therapy. While the HeartMate 3 pump confers a lower risk of device thrombosis and ischemic stroke, anticoagulation therapy with warfarin is still required. Patient education about nutritional and herbal therapies is important to reduce the potential for interference with anticoagulant and antiplatelet management. Regular review of programmatic clinical practice guidelines and practitioner adherence to GDMT recommendations, mean arterial pressure goals, and time in therapeutic range for anticoagulation on LVAD support should be considered to ensure optimal outcomes are achieved for more patients on LVAD support. The HFSA Expert Consensus Statement on the Medical Management of Patients on Durable Mechanical Circulatory Support is published in the Journal of Cardiac Failure and available online at . DOI: 10.1016/j.cardfail.2023.01.009 About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. About the Journal of Cardiac Failure The Journal of Cardiac Failure publishes peer-reviewed manuscripts of interest to clinicians and researchers in the field of heart failure and related disciplines. These include original communications of scientific importance and review articles involving clinical research, health services and outcomes research, animal studies, and bench research with potential clinical applications to heart failure. The Journal also publishes manuscripts that report the design of ongoing clinical trials and editorial perspectives that comment on new developments pertinent to the field of heart failure or manuscripts published in other journals. Learn more at . Media Contact: Laura Poko 301-798-4493, ext. 226 [email protected] SOURCE Heart Failure Society of America

看似平静的睡眠过程暗藏着许多疾病风险。其中最为典型的就是人类健康“头号杀手”心血管疾病。以脑卒中为例，该病多发作于夜间休息过程中。且夜间发作脑卒中易被忽视，也容易失去救治的黄金时机。因此，夜间心脑血管疾病突发往往会导致高死亡率。国家心血管病中心的发布的《中国心血管健康与疾病报告2020》数据显示，中国心血管病现患人数2.9亿，城乡居民疾病死亡构成比中，心血管病占首位。2018年农村、城市心血管病分别占死因的46.66%和43.81%。每5例死亡中就有2例死于心血管疾病。因此，降低心血管疾病发病率和死亡率迫在眉睫。而做好夜间血压监测以及心脑血管疾病的预防，是减少疾病发生风险的重要工作。对此，以原研技术为核心的施林普，开发出了精准的疾病风险预防监护及慢病健康管理的人工智能平台。 医疗级夜间连续监测，实现心脑血管疾病精准预防施林普依托睡眠监护设备SC-500，对人体心率、呼吸、血压、睡眠、心血管、认知症等体征数据进行无感式采集和数据监测，以此分析长期变化趋势，解析用户健康状态。同时结合采集数据的生命健康预警系统，对用户健康进行全程化管理，实现用户自主监测、家庭互查、数据共享、平台预防服务的生态管理。而且该设备使用起来十分方便，用户只要将产品垫在床下。用户躺在床上休息时，施林普的传感器就能“听”到血液在血管里流动的回声。施林普创始人兼总经理李东泉向动脉网介绍了一个非常形象的类比：“一个密闭的油罐箱，该如何判断里面有多少油呢？一般就在油罐箱表皮上贴一个ECM麦克风传感器，通过麦克风听油罐箱里面的回声，不同油量流动时的回声不一样。我们的传感器则可以覆盖0.01Hz－10kHz的震频，所以能根据血液在血管内的回声对心血管状态进行研究。”但工业上油罐箱是固定的，没有弹性，听回声相对容易。人体血管却有伸缩弹性的，所以单纯是传感器“听”到的数据还不够准确。为解决这个问题，施林普耗时三年，通过心率变异性（HRV）推断血管柔韧性，并结合血液流动的回声信号，构建了AI心血管评估3D模型，评估侧重主要集中在以下两方面。第一个是血管狭窄。据李东泉介绍，血管狭窄处的血液流动呈喷射状，表现为漩涡回声。当冬季到来，血管壁比较薄，血管韧性较差，血液流动又是喷射状，很容易造成血管壁破裂，引发脑出血。第二个是血管梗塞。梗塞其实是斑块堆积导致血管堵塞面积达70%甚至更多，脑梗、心梗都存在这样的问题。对此，施林普制定了一个监测预警区间，用户心血管变异指数高于1.2则有脑溢血风险，低于0.6则有梗塞风险。当监测数据连续三天超出该区间，平台会立即建议用户就医诊治。该3D血管评估系统与多普勒超声检测对标后的吻合度达84.5%，并在日本取得了医疗器械证。目前经平台推荐就医后的疾病确诊率较高，未有误报情况出现。打造“中国第一个健康入口”2020年，施林普与开滦总医院开展了一项创新研究，即建立基于LF（低频成分）/HF（高频成分）的精神压力、疲劳监测预警等临床医学AI，用于情绪焦虑、抑郁以及认知症的判定。李东泉介绍称，白天以交感神经为主导来支配我们的四肢运动，夜晚则由迷走神经主导。而交感神经和迷走神经的活动情况是判别焦虑、抑郁甚至认知症的重要参数。两类神经的活动切换结合大脑皮层指数与人工智能算法，便可以对上述疾病进行监测预警。2021年，公司在开滦总医院进行了1050例临床试验，RCT数据显示该平台的算法平均准确率为92%，最高可达98%。“我们平台的价值还体现在数据采集的时间点。高血压、糖尿病、心血管等绝大部分慢性病，一定是夜间迷走神经和交感神经切换时的数据极具价值。”李东泉说道。以心血管疾病为例，夜晚人体血管舒张性差，一旦发生堵塞容易造成大面积缺血，引发脑梗/心梗，所以夜间采集监测数据价值更高。血压也是同理，白天有舒张压的影响，可能不够精准。但如果夜晚安静时血压仍有问题，那么疾病风险已近在咫尺。而施林普的产品核心能力就是夜间连续采集，并且采集到用户的心率、呼吸、血压、心血管变异性等各项数据。无论是疾病发生前的监测预警还是治疗后的康复追踪，都可以通过该平台进行管理，是用户健康管理的重要一环。因此，施林普也找到了自身的精准定位。“我们不做治疗，就是专注于监测。但一个能做到如此精准采集、使用如此便捷的监测设备或平台，无疑是有助于增强用户使用粘性的。所以，医院康复科、保险公司、互联网医院、大健康管理平台等都可以是我们的合作伙伴。”李东泉介绍道。目前，智能可穿戴监测产品最大的问题之一还是数据的准确性和连续性。即便是单导联的监测方式，用户使用时如果贴放位置不恰当，也会对数据采集的真实性、精准性和连续性造成影响。而施林普的监测设备可以置于床垫之下，用户睡眠时可以进行无感采集。所以，施林普的心脑血管监测预防服务每天会产生大量的精准C端用户数据，可以嵌入到任何一个健康管理平台。基于此，施林普的愿景就是打造“中国第一个健康入口”。目前，施林普已经与中国人民解放军总医院、空军特色医学中心、广州医科大学第一附属医院、开滦总医院、首都医科大学北京朝阳医院、北京航空航天大学等医疗机构和高效展开了紧密的产学研合作。自主研发，首创低频ECM传感及数字滤波技术在物联网医疗飞速发展的今天，传感器作为数据采集的源头，十分关键。但与芯片的“显性”卡脖子不同，传感器的卡脖子尚未引起产业的足够重视。在关键技术、高附加值的产业应用领域，能够掌握高精度传感器技术的企业凤毛麟角，施林普就是其中之一。据李东泉介绍，传统工业ECM传感器通常仅能采集到1Hz－1kHz的震动频段信号。而医疗上人体生命体征的低频信号，低频噪声干扰大，采集与信息分离都十分困难。针对这些难点，施林普的原创ECM传感器可测量百万分之一的压力变动，覆盖0.01Hz－10kHz之间的所有低频震颤信号，是公司的核心技术之一。并且，公司早在2003年就在日本拿到了该传感器的发明专利。拿到专利后，施林普研发团队又十年如一日地投入到信号采集后的又一核心技术——信号滤波。把身体体征的低频震颤信号分离出来。信号采集、分离完成之后，便迎来了基于AI算法技术的产品价值验证阶段。第一个适应症是心电监测。只有和心电监护仪ECG这类医疗级采集方式做对比，并达到较高程度的吻合率，产品才具备临床应用价值，否则就会沦为普通的电子产品，能监测体征变化却不精准。2013年，公司开始做对比验证，结果显示，施林普在生命体征信号处理（心率、呼吸、BCG）对标医疗器械的一致率达95%以上，并于2018年拿到了二类医疗器械注册证。第二个适应症是呼吸监测。传统的医院检查呼吸需要使用鼻塞器（感应器），通过鼻塞器的波动来判定呼吸暂停、呼吸间歇、呼吸低通量等情况。而施林普的电子采集方式在用户睡眠之中就能够完成检测监测，敏感度和精度都很高，并获批了二类医疗器械认证。其实，心率和呼吸在睡眠时存在耦合关系。2005年哈佛医学院的睡眠专家团队将这种关系确定为心肺耦合（CPC）。人体在睡眠过程中会经历从清醒、浅睡到熟睡的周期性循环，还可能会出现一些与梦境相关的快速动眼睡眠。CPC可以判断每一睡眠阶段发生的时间和比例并刻画出睡眠结构，提示用户是否存在睡眠的问题。李东泉（左）代表公司接受天使联合汇颁奖因此，心电、呼吸的适应症覆盖完成后，施林普将应用场景进一步延展整合至了睡眠监测领域。目前，该睡眠监护设备SC-500已用于广东，北京，上海，河北，河南等地的多家三甲医院。近日，施林普平台公司还获得了2022天使联合汇第三季度项目路演沙龙的一等奖。想要联系动脉网报道的企业，请点击文末左下方“阅读原文”填写表单，我们的工作人员将征求企业意见后，尽快为您服务。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。动脉网，未来医疗服务平台